Experience from melanoma brain metastases shows that combining BRAF/MEK inhibitors with PD-1/CTLA-4 checkpoint inhibitors improves intracranial tumor control [15], and some authors have extrapolated this approach to primary meningeal melanoma. This evidence concerns the gene CTLA4 and leptomeningeal melanoma.